{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"costeff-syndrome","columns":[{"gene":"","key":"MONDO:0009787/OMIM:258501","label":"3-methylglutaconic aciduria, type III","mondoId":"MONDO:0009787","onsetQualifier":null,"recordKeys":["1f106e2a43e68a5eb7157c373ef8fcd973d1c90fadcaed8a31e9ef002e290ddd","1f83987661f343f16767b5dd79d29c95d635bc9109eae514946b210b42a93b0e","5d3e55a04910ebdc353d8b3c60ea1a87aa36847df7b82d1be2ab9868146bc34a","686dd806a7df3dbffa62122092b6fd57a276775c7669e401b5d490f30c2fa240","68b38fdb7637a99fba5e5798ed05bea2915d55e6fadd00b6b5a8759c1193beec","9454360cfc3fe9590c70a516de5cdb6b3e117b00fea1be05cc4f82a5545a6613","9777cdceb3fa0b3ca8f04da2f2441023795765bde0c5af0968e178113c1f74e8","97eb9f5df28672bade8e5e5c8d29cc15baec9bb601a5a0a59619cacbd84c174a","a1cc39d552f07ea556ef614142c2098411653841bfec0a9a76709f827985ceae","a49562cfedbe7a20ea19e803883bfcfb6e51694b340aebe2c2878d2adc017f93","acd068458f8b2fe5a7cb3e37e6a81b0a6bdca46d1c7089ef8cbbf5d5430ce7a1","c0e983201250802030e25516036ce8f3b9a08d6d1658beea7755c985c269cca6","ddbc1b634e1146b7d8321c919ce3bf9b1791bb335c8b5bae294873e4357b049d"],"recordQualifiers":{},"scopeLabel":"OMIM:258501","sourceIds":["OMIM:258501"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."},{"gene":"","key":"MONDO:0009787/ORPHA:67047","label":"3-methylglutaconic aciduria type 3","mondoId":"MONDO:0009787","onsetQualifier":null,"recordKeys":["0f94798b18f7fd16232a027917764c1581775b006d57218be48da4f6f5f2b74a","16f87fa5953a08fd8db87f6524099dfa8e8f241f4b3b446017d45bcfa27a420f","2a5c5f112d18fd9fbcb285eb60d57045c47b0fdf0e272dc95d7c41fe3d8200a6","3199668db7642f046d5794f12e29c14c069dac90fb7573ea1c84547b37507b4e","4326d46f89e572a60097b0517ed55314843f60b3279f364b40862d26fd5f0622","55d265e9d7fa3fe0cfc4eb7cfdbe5740094d9c403fc6f785885eb8bf33d6ba9c","93b534a990e163d29061be9beeb742dc17331a426e2ff1960cc4211d0876523c","bf2f5114f9582c710e8b7ac19e1338f432063b0ba3082c13e50d9e9264044750","f0bf15c51ea33b99ceec43d11e0e6af12e38246886cc6daec3b154b5ff98a3b0"],"recordQualifiers":{},"scopeLabel":"ORPHA:67047","sourceIds":["ORPHA:67047"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"comparison":{"collapseColumnsLabel":"Show initial comparisons","defaultColumnKeys":["MONDO:0009787/OMIM:258501","MONDO:0009787/ORPHA:67047"],"expandColumnsLabel":"Compare all source entries","intro":"Compare the original source entries. Different entries may describe different patient groups.","primaryFeatureIds":[],"scopeNoteHtml":"<p>Each column keeps its native condition scope. Initial features are displayed alphabetically, not ranked by clinical importance. Counts remain separate, and an empty cell does not mean a feature cannot occur.</p>"},"coverage":{"countRecords":3,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":22,"sourceGroups":{"omim":7,"orphanet":9,"published":6}},"features":[{"hpoId":"HP:0003535","label":"3-Methylglutaconic aciduria","primary":false},{"hpoId":"HP:0003344","label":"3-Methylglutaric aciduria","primary":false},{"hpoId":"HP:0002071","label":"Abnormality of extrapyramidal motor function","primary":false},{"hpoId":"HP:0001251","label":"Ataxia (coordination difficulty)","primary":false},{"hpoId":"HP:0003487","label":"Babinski sign","primary":false},{"hpoId":"HP:0002072","label":"Chorea (involuntary movements)","primary":false},{"hpoId":"HP:0001266","label":"Choreoathetosis","primary":false},{"hpoId":"HP:0100543","label":"Cognitive impairment","primary":false},{"hpoId":"HP:0001260","label":"Dysarthria","primary":false},{"hpoId":"HP:0001288","label":"Gait disturbance","primary":false},{"hpoId":"HP:0001347","label":"Hyperreflexia","primary":false},{"hpoId":"HP:0001249","label":"Intellectual disability","primary":false},{"hpoId":"HP:0000639","label":"Nystagmus","primary":false},{"hpoId":"HP:0000648","label":"Optic atrophy","primary":false},{"hpoId":"HP:0007663","label":"Reduced visual acuity","primary":false},{"hpoId":"HP:0002313","label":"Spastic paraparesis","primary":false},{"hpoId":"HP:0001257","label":"Spasticity","primary":false},{"hpoId":"HP:0000505","label":"Visual impairment","primary":false}],"ledeHtml":"A patient-friendly description is not yet available in the ingested narrative sources for this condition.","mondoId":"MONDO:0009787","records":[{"frequencyKind":"range","key":"0f94798b18f7fd16232a027917764c1581775b006d57218be48da4f6f5f2b74a","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001249","is_excluded":false,"label":"Intellectual disability","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"16f87fa5953a08fd8db87f6524099dfa8e8f241f4b3b446017d45bcfa27a420f","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0003535","is_excluded":false,"label":"3-Methylglutaconic aciduria","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"1f106e2a43e68a5eb7157c373ef8fcd973d1c90fadcaed8a31e9ef002e290ddd","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0001251","is_excluded":false,"label":"Ataxia","onset_id":null,"reference":"PMID:11668429","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"1f83987661f343f16767b5dd79d29c95d635bc9109eae514946b210b42a93b0e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002072","is_excluded":false,"label":"Chorea","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"2a5c5f112d18fd9fbcb285eb60d57045c47b0fdf0e272dc95d7c41fe3d8200a6","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001266","is_excluded":false,"label":"Choreoathetosis","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"3199668db7642f046d5794f12e29c14c069dac90fb7573ea1c84547b37507b4e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002313","is_excluded":false,"label":"Spastic paraparesis","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"4326d46f89e572a60097b0517ed55314843f60b3279f364b40862d26fd5f0622","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001288","is_excluded":false,"label":"Gait disturbance","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"55d265e9d7fa3fe0cfc4eb7cfdbe5740094d9c403fc6f785885eb8bf33d6ba9c","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001251","is_excluded":false,"label":"Ataxia","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"5d3e55a04910ebdc353d8b3c60ea1a87aa36847df7b82d1be2ab9868146bc34a","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0100543","is_excluded":false,"label":"Cognitive impairment","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"686dd806a7df3dbffa62122092b6fd57a276775c7669e401b5d490f30c2fa240","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0001257","is_excluded":false,"label":"Spasticity","onset_id":null,"reference":"PMID:11668429","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"68b38fdb7637a99fba5e5798ed05bea2915d55e6fadd00b6b5a8759c1193beec","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001260","is_excluded":false,"label":"Dysarthria","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"93b534a990e163d29061be9beeb742dc17331a426e2ff1960cc4211d0876523c","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000639","is_excluded":false,"label":"Nystagmus","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"9454360cfc3fe9590c70a516de5cdb6b3e117b00fea1be05cc4f82a5545a6613","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"PCS","frequency_raw":"10/10","hpo_id":"HP:0003344","is_excluded":false,"label":"3-Methylglutaric aciduria","onset_id":null,"reference":"PMID:11668429","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"9777cdceb3fa0b3ca8f04da2f2441023795765bde0c5af0968e178113c1f74e8","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"PCS","frequency_raw":"10/10","hpo_id":"HP:0000648","is_excluded":false,"label":"Optic atrophy","onset_id":null,"reference":"PMID:11668429","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"97eb9f5df28672bade8e5e5c8d29cc15baec9bb601a5a0a59619cacbd84c174a","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0007663","is_excluded":false,"label":"Reduced visual acuity","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"a1cc39d552f07ea556ef614142c2098411653841bfec0a9a76709f827985ceae","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"PCS","frequency_raw":"10/10","hpo_id":"HP:0003535","is_excluded":false,"label":"3-Methylglutaconic aciduria","onset_id":null,"reference":"PMID:11668429","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"a49562cfedbe7a20ea19e803883bfcfb6e51694b340aebe2c2878d2adc017f93","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0002071","is_excluded":false,"label":"Abnormality of extrapyramidal motor function","onset_id":null,"reference":"PMID:11668429","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"acd068458f8b2fe5a7cb3e37e6a81b0a6bdca46d1c7089ef8cbbf5d5430ce7a1","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003487","is_excluded":false,"label":"Babinski sign","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"bf2f5114f9582c710e8b7ac19e1338f432063b0ba3082c13e50d9e9264044750","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001260","is_excluded":false,"label":"Dysarthria","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"c0e983201250802030e25516036ce8f3b9a08d6d1658beea7755c985c269cca6","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001347","is_excluded":false,"label":"Hyperreflexia","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"ddbc1b634e1146b7d8321c919ce3bf9b1791bb335c8b5bae294873e4357b049d","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000505","is_excluded":false,"label":"Visual impairment","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"f0bf15c51ea33b99ceec43d11e0e6af12e38246886cc6daec3b154b5ff98a3b0","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000505","is_excluded":false,"label":"Visual impairment","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p>No mapped MedlinePlus condition document in this snapshot.</p>","identityNote":"MONDO defines condition identity and route membership. Native evidence populations and narrative coverage retain their separate scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>No MedlinePlus narrative has been mapped to this MONDO condition. Feature annotations, when available, are retained below.</p>","key":"overview","title":"Condition overview"}],"sharedSources":[],"slug":"costeff","sourceDocuments":[],"sourceNote":"MONDO condition identity; scoped MedlinePlus enrichment where available; original HPO annotations.","takeawayHtml":"Cause information is not available in the mapped narrative sources for this condition.","title":"3-methylglutaconic aciduria type 3"},"schemaVersion":1}